Table 2 Results of chemotherapy for brain metastases (some trials also included patients with previous radiotherapy)
From: Integration of chemotherapy into current treatment strategies for brain metastases from solid tumors
Reference | n (patients) | Regimen | OR rate | Median TTP | Median OS |
|---|---|---|---|---|---|
Bafaloukos et al. 2004 [12] | 25 melanoma | Temozolomide alone or plus cisplatin or docetaxel | 24% | 2.0 | 4.7 |
Hwu et al. 2005 [13] | 26 melanoma | Temozolomide plus thalidomide | 12% | Not given | 5.0 |
Agarwala et al. 2004 [14] | 151 melanoma | Temozolomide alone | 7% | 1.1 (PFS) | 3.2 |
Christodoulou et al. 2001 [15] | 28 various | Temozolomide alone | 4% | 3.0 | 4.5 |
Abrey et al. 2001 [16] | 41 various | Temozolomide alone | 6% | 2.0 | 6.6 |
Caraglia et al. 2006 [17] | 19 various | Temozolomide plus pegylated liposomal doxorubicin | 37% | 5.5 (PFS) | 10.0 |
Christodoulou et al. 2005 [18] | 32 various | Temozolomide plus cisplatin | 31% | 2.9 | 5.5 |
Oberhoff et al. 2001 [19] | 24 breast ca | Topotecan | 25% | 4.1 (response duration) | 6.3 |
Korfel et al. 2002 [20] | 30 SCLC | Topotecan | 33% | 3.1 | 3.6 |
Bernardo et al. 2002 [21] | 22 NSCLC | Vinorelbine plus gemcitabine and carboplatin | 45% | 5.7 (response duration) | 7.6 |
Cortes et al. 2003 [10] | 26 NSCLC | Paclitaxel/cisplatin plus either vinorelbine or gemcitabine | 38% | 2.9 | 4.9* |
Franciosi et al. 1999 [22] | 116 various | Cisplatin plus etoposide | 38%1 30%2 0%3 | 3.9 3.9 2.5 | 7.1 7.3 3.9 |
Jacquillat et al. 1990 [23] | 36 melanoma | Fotemustine | 25% | Not given | Not given |
Boogerd et al. 1992 [24] | 22 breast ca | Cyclophosphamide, 5-fluoro-uracil and methotrexate or doxorubicin | 55% | Not given | 5.7 |
Kaba et al. 1997 [25] | 97 various | Thioguanine, procarbazine, dibromodulcitol, CCNU, fluorouracil and hydroxyurea | 28% | 2.8 | 5.7 |